Targeting mTOR combined with ibrutinib was also suggested in ABC-DLBCL by Phelan et al. as mTORC1/2 inhibitor AZD2014 further attenuates formation of MYD88/TLR9/BCR super-complex when compared to ibrutinib alone (115). This evidence concerns the gene BCR and aneurysmal bone cyst.